Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

ImmunityBio (IBRX) Profit After Tax: 2014-2025

Historic Profit After Tax for ImmunityBio (IBRX) over the last 12 years, with Sep 2025 value amounting to -$67.3 million.

  • ImmunityBio's Profit After Tax rose 21.55% to -$67.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$348.7 million, marking a year-over-year increase of 40.69%. This contributed to the annual value of -$413.6 million for FY2024, which is 29.15% up from last year.
  • As of Q3 2025, ImmunityBio's Profit After Tax stood at -$67.3 million, which was up 27.33% from -$92.6 million recorded in Q2 2025.
  • ImmunityBio's Profit After Tax's 5-year high stood at -$59.2 million during Q4 2024, with a 5-year trough of -$233.4 million in Q4 2023.
  • For the 3-year period, ImmunityBio's Profit After Tax averaged around -$117.0 million, with its median value being -$116.6 million (2023).
  • Per our database at Business Quant, ImmunityBio's Profit After Tax tumbled by 184.93% in 2021 and then surged by 74.65% in 2024.
  • Over the past 5 years, ImmunityBio's Profit After Tax (Quarterly) stood at -$91.6 million in 2021, then fell by 18.32% to -$108.3 million in 2022, then crashed by 115.47% to -$233.4 million in 2023, then soared by 74.65% to -$59.2 million in 2024, then rose by 21.55% to -$67.3 million in 2025.
  • Its Profit After Tax was -$67.3 million in Q3 2025, compared to -$92.6 million in Q2 2025 and -$129.7 million in Q1 2025.